Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + gemcitabine with or without ACP-196 (acalabrutinib) in previously untreated metastatic pancreatic cancer
2015-003428-30Phase 2Terminated
- Sponsor
- Acerta Pharma
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acalabrutinib in pancreatic cancer (PDAC) (2 arms), sponsored by Acerta Pharma. Primary endpoint: overall_response_rate. Started Dec 2015; status: terminated.
02
Drugs
acalabrutinib
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2015-003428-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003428-30.